A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Ehsan Jozaghi; Andrew A. Reid; Martin A. Andresen

Summary

Collection(s)	Collection(s) DC Faculty Research & Scholarship
Content type	Content type Digital Document
Resource Type	Resource Type Text
Genre	Genre article
Language	Language English
Peer Review Status	Peer Review Status Peer Reviewed

Persons and Affiliations

Persons	Author (aut): Jozaghi, Ehsan Author (aut): Reid, Andrew A. Author (aut): Andresen, Martin A.

Origin Information

Date Created/Date Issued	2013
Publisher	Springer Nature Switzerland AG

Abstract/Description

Abstract

Background:
This paper will determine whether expanding Insite (North America’s first and only supervised injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not having such expanded programs for injection drug users.

Methods:
By analyzing secondary data gathered in 2012, this paper relies on mathematical models to estimate the number of new HIV and Hepatitis C (HCV) infections prevented as a result of additional SIF locations in Montreal.

Results:
With very conservative estimates, it is predicted that the addition of each supervised injection facility (up-to a maximum of three) in Montreal will on average prevent 11 cases of HIV and 65 cases of HCV each year. As a result, there is a net cost saving of CDN$0.686 million (HIV) and CDN$0.8 million (HCV) for each additional supervised injection site each year. This translates into a net average benefit-cost ratio of 1.21: 1 for both HIV and HCV.

Conclusions:
Funding supervised injection facilities in Montreal appears to be an efficient and effective use of financial resources in the public health domain.

Publication/Container Information

Publication Title	Publication Title Substance Abuse Treatment, Prevention, and Policy
Publication Number	Publication Number Issue 8

Physical Description

Physical Description Note	Physical Description Note PUBLISHED

Identifiers

DOI	DOI 10.1186/1747-597X-8-25
ISSN	ISSN 1747-597X

Notes

Note

Note	publication status: Final article published

Access and Rights

Identifier URI	Identifier URI https://substanceabusepolicy.biomedcentral.com/articles/10.1186/1747-597X-8-25
Use and Reproduction	Use and Reproduction ©2013. The Authors.
Rights Statement	Rights Statement IN COPYRIGHT - EDUCATIONAL USE PERMITTED

Subjects and Classifications

Keywords	Keywords Supervised injection facility Cost-effectiveness Cost-benefit Harm reduction

Relationships

Language	English
Name	A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada
Authored on	2024-12-10
MIME type	application/pdf
File size	315053
Media Use	Original File

A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Cite this

Download

Share